Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology
Thomas W. Flaig(University of Colorado Denver), Alyse Johnson-Chilla(National Comprehensive Cancer Network)
Cited by 627
Related Papers
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2015|1.4k
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|560
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
|Journal of the National Comprehensive Cancer Network|2020|484
NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018
|Journal of the National Comprehensive Cancer Network|2018|370